Application of 2-methoxyestradiol in treatment of systemic lupus erythematosus

A technology of dimethoxyestradiol and lupus erythematosus is applied in the field of biomedicine and can solve the problems of inducing body infection, inability to directly inhibit drugs and preparations, and obvious toxic and side effects.

Inactive Publication Date: 2014-12-10
THE THIRD AFFILIATED HOSPITAL INST OF FIELD SURGERY OF PLA ARMY MEDICAL UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the leading clinical treatment for SLE is the use of hormones and non-specific immunosuppressants, such as glucocorticoids, cyclophosphamide, etc. These drugs can extensively inhibit immune cells and effectively control the course of the disease, but the side effects are obvious, such as Destroy gastric mucosa to form gastritis, induce body infection, lead to osteoporosis, etc.
Since the existence of a large number of autoantibodies in serum is the basic pathological feature of SLE, it is suggested that suppressing the level of autoantibodies in patients with systemic lupus erythematosus is the direction of treatment for SLE, but there are no drugs and preparations that can directly inhibit the production of autoantibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 2-methoxyestradiol in treatment of systemic lupus erythematosus
  • Application of 2-methoxyestradiol in treatment of systemic lupus erythematosus
  • Application of 2-methoxyestradiol in treatment of systemic lupus erythematosus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Embodiment 1: Model mice: SPF level SLE model B6.MRL-Fas (lpr) female mice (purchased from Institute of Model Animals, Nanjing University, China), all 18-20g, were randomly divided into experimental group and control group, After feeding until 18 weeks old, the mental state, behavior and posture of the mice were observed, and the lymph nodes in each part were checked by touch. Mice were killed by ether anesthesia, dissected and observed changes in lymph nodes, kidneys and spleen with naked eyes, and then harvested lymph nodes, kidneys, spleen, thyroid and liver tissues. Dimethoxyestradiol (2ME2) ​​administration method (dissolved in dimethyl sulfoxide): (1) When the mice were 15 weeks old, inject 0.75uM / kg / time into the tail vein, once a day, for three consecutive weeks or (2) when the mice were 15 weeks old, gavage 100uM / kg / time, once a day, and gavage continuously for three weeks;

[0014] Results: (1) 2ME2 can control the level of anti-ds-DNA antibody in lupus mice:...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of 2-methoxyestradiol (2ME2) in treatment of systemic lupus erythematosus. 2ME2 can be used as a therapeutic medicine for systemic lupus erythematosus or a component contained in the therapeutic medicines. The systemic lupus erythematosus includes cutaneous lupus, lupus nephritis, lupus encephalopathy and other systemic or/and organic lupus diseases. 2ME2 is given in a tail vein injection manner with a dosage of 0.75 mu M/kg each time, or is given in an intragastric manner with a dosage of 100mu M/kg each time. 2ME2 is used for treating B6.MRL-Fas(lpr) mice. When used for treating lupus erythematosus model mice (MRL-Fas(lpr) mice), 2ME2 has the beneficial effects of lowering the autoantibody level of lupus erythematosus, reducing syndromes of nephritis related to lupus, and relieving lupus syndromes.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the use of dimethoxyestradiol in treating systemic lupus erythematosus. Background technique [0002] Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by pathogenic autoantibodies. The direct pathogenic factor is polyclonal autoantibodies, which cause damage to various tissues and organs in the form of immune complexes. At present, the leading clinical treatment for SLE is the use of hormones and non-specific immunosuppressants, such as glucocorticoids, cyclophosphamide, etc. These drugs can extensively inhibit immune cells and effectively control the course of the disease, but the side effects are obvious, such as Destroy gastric mucosa to form gastritis, induce body infection, and lead to osteoporosis. Since the existence of a large number of autoantibodies in the serum is the basic pathological feature of SLE, it is suggested that inhibiting the level of autoa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/565A61P37/02
Inventor 邓少丽罗杰
Owner THE THIRD AFFILIATED HOSPITAL INST OF FIELD SURGERY OF PLA ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap